Business Wire

New Study Reveals Tech Industry Leads AI Adoption in Support Operations at 92%; Regulated Industries Only at 58% Due to Compliance Constraints

12.11.2025 15:06:00 CET | Business Wire | Press Release

Share

Today, Deskpro, provider of the secure AI-powered help desk platform, released results from the State of AI in Support Operations: Balancing Innovation and Compliance report, which quantifies how security and compliance requirements are creating distinct market segments with vastly different AI adoption rates. According to the data, 92% of technology companies are adopting AI for support operations, while companies in regulated industries are significantly lagging behind with a 58% adoption rate. This 34-point gap reflects a significant disconnect: organizations are eager to adopt AI-powered support solutions, but face significant barriers related to data security, compliance and regulatory requirements, and deployment flexibility. While market demand for AI support capabilities exists across all sectors, constraints lie in how compliance mandates and data privacy concerns limit deployment options.

AI Adoption Rates Differ Greatly Between Tech and Regulated Industries with Security Emerging as Key Factor

According to the report, security has moved from a feature to a veto power in the technology procurement process. Eighty-one percent of organizations rate security as “critical” or “very important” when evaluating support technology, and 78% require IT or security team involvement in final technology purchasing decisions. This means IT and security leaders are controlling whether solutions get adopted, regardless of other platform capabilities. However, the timing of security validation differs dramatically by sector, explaining the wide AI adoption gap between industries:

  • Technology companies demonstrate a more reactive security posture with 41% of respondents stating a security incident as a potential trigger for prioritizing AI security, and 45% citing industry regulations. This flexibility allows technology companies to move fast with AI adoption because they tend to validate security and address compliance after deployment.
  • Regulated industries face strict compliance mandates (HIPAA, PCI DSS, FedRAMP) that require security and compliance validation before deployment. Security awareness is equally high: 64% in financial services and 61% in healthcare cite compliance requirements as important security drivers. Yet adoption lags significantly (86% in financial services, 39% in healthcare and 50% in government). This deployment gap reflects a difference in regulatory structure where compliance mandates require pre-deployment validation, not post-deployment remediation.

“The AI adoption gap isn’t a technology problem, it’s an architecture problem,” said Brad Murdoch, CEO of Deskpro. “Technology companies can adopt cloud-based AI because they're willing to move fast and validate security reactively. Financial services, healthcare, aerospace, and governments can’t do that. They need solutions that meet compliance requirements before deployment, not after. That architectural difference is precisely why current solutions are inadequate in regulated markets. The solutions winning in tech are structurally incompatible with regulated industries’ needs.”

Majority of Organizations to Increase Focus on AI Security as Part of Implementation Requirements

The market is currently in an active transition. Fifty-three percent of organizations report they are currently in the pilot, planning, or active evaluation phases of AI implementation in their support operations, and focusing on defining their requirements before committing to long-term vendor partnerships. Additionally, 74% of organizations expect their focus on AI security to increase significantly over the next two years, signaling accelerating demand for solutions that address both innovation and compliance requirements simultaneously.

“Organizations are asking themselves a fundamental question: do I have to choose between AI capabilities and data sovereignty? The answer should be no,” continued Brad Murdoch, CEO of Deskpro. “The market is demanding solutions that deliver production-grade AI while keeping data within their own infrastructure and giving them freedom to choose their own AI providers. That combination is what will define the next generation of enterprise software.”

Research Methodology

This analysis is based on a survey of 220+ professionals across IT, customer support, and HR functions conducted in 2025. Respondents represent organizations of varying sizes across technology, healthcare, financial services, government, and other sectors. The survey examined AI adoption patterns, security decision-making, compliance requirements, and organizational constraints.

Read the Full Report

Download the full State of AI in Support Operations: Balancing Innovation and Compliance surveyreport to explore adoption patterns by industry and organization type, specific compliance barriers by sector, deployment model preferences, and strategic recommendations for navigating the evolving AI-enabled help desk market.

Resources

About Deskpro

Deskpro is the developer of AI-driven help desk software that empowers organizations worldwide to deliver exceptional customer and employee experiences that translate directly into tangible ROI, through improved customer and agent retention. Deskpro is the only help desk platform with enterprise-grade security, compliance, and data privacy, enabling all organizations to adopt and deploy AI, even in the most regulated industries and sovereign environments. Deskpro is available as a cloud service, and can also be deployed in VPCs, on-premise, private clouds, and sovereign clouds. Trusted by leading enterprises worldwide in banking, technology, financial services, healthcare systems, aerospace and defense, as well as government agencies, Deskpro is led by experts in enterprise software, customer experience, and customer support. Learn more at Deskpro.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251112702468/en/

Contacts

Media Contact
Stephanie Floyd
Bhava Communications for Deskpro
deskpro@bhavacom.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye